Glanzmann thrombasthenia is a rare inherited bleeding condition in which a person has a normal number of platelets that cannot stick to each other, so bleeding takes much longer than usual to stop [1,5].
This page provides general information. It does not replace advice from a doctor or another qualified healthcare professional.
When a blood vessel is damaged, small blood cells called platelets rush to the injury, stick to the vessel wall, then clump together into a plug that seals the leak [5,17].
The clumping step needs a receptor on the platelet surface called integrin alpha-IIb-beta-3, written in older sources as glycoprotein IIb/IIIa. Think of it as a docking point. A blood protein called fibrinogen locks into the docking point on one platelet and into the same point on the next, holding the two together [1,3,5].
In Glanzmann thrombasthenia that docking point is missing, too scarce, or shaped so fibrinogen cannot lock in. Platelets still arrive and still stick to the vessel wall, and they cannot hold on to each other, so no firm plug forms [1,5].
There are three forms, set by how much receptor is present. Type I, the most common, has under 5 percent of the usual amount, type II has roughly 5 to 20 percent, and in the variant form, sometimes called type III, a reasonable amount is there and does not work [1,3].
It is also called Glanzmann disease, and older writing uses the possessive form Glanzmann’s thrombasthenia [1]. Two conditions are confused with it: acquired Glanzmann thrombasthenia, which is not inherited and happens when antibodies block the same receptor, and hemophilia, where the platelets work and a clotting protein is missing [3,6,12].
Published estimates put it at about 1 in a million people worldwide [1,6,17]. That counts people already diagnosed, and since diagnosis needs a specialist laboratory the true number is probably higher where those are scarce [3].
It is much more common where marriage between close relatives is usual, since both parents are then more likely to carry the same rare gene change. Communities described in the literature include Romani communities in France, South Indian Hindu communities and Iraqi Jewish families [3,4]. Males and females are affected equally [1,5].
Regional counts are not comparable. The United Kingdom has roughly 149 recorded cases [6], and one Iranian series described 382 people [14]. A 2025 study in Upper Egypt described 131 people and estimated more than 1 in 200,000 locally [13].
Genes are instructions inside our cells. Two genes carry the instructions for the halves of the receptor: ITGA2B and ITGB3, both on chromosome 17. A change in either, often called a gene variant, can leave the receptor missing or unable to work [1,3].
The condition is autosomal recessive. Autosomal means the gene is not on the chromosomes that determine sex. Recessive means a person needs a changed copy from each parent for the condition to appear [1,2].
Each parent carries one changed copy and one working copy. Carriers are usually well and often have no idea until a child is diagnosed [2,5]. For two carriers, each pregnancy carries a 1 in 4 chance of a child having the condition and a 2 in 4 chance of a carrier [2].
Genetic counseling and family testing are offered, since the exact gene change allows accurate advice for relatives [3].
Bleeding usually starts in the first year or two of life, often with bruising, nosebleeds or bleeding gums, and severity varies a great deal, even within one family [1,3].
Common features include [1,3,5]:
Bleeding from the gut affects a minority, and bleeding into joints or the head is uncommon [1,3]. Bleeding out of the blue tends to settle with age, though heavy periods and bleeding around childbirth do not [1,3].
When to seek urgent help. Contact your treatment center or seek emergency care for bleeding that will not stop with pressure, vomiting blood, black or bloody stools, heavy bleeding after childbirth, or any head injury. Headache, neck ache, drowsiness or loss of consciousness after a knock to the head needs immediate attention [6,12]. Asking early matters, since delay is linked to longer stays in hospital [4].
This is the part most worth understanding. A routine full blood count measures how many platelets a person has. Here that number is normal, and the platelets look normal under a microscope [3,5,6]. The standard clotting tests, prothrombin time and activated partial thromboplastin time, are normal too [3]. A person can be bleeding heavily and still be told their blood tests are fine. That is a real pattern, not a mistake, and it is why the condition is easy to miss.
The tests that find it need a specialist laboratory, usually at a bleeding disorder treatment center [3,5]:
Tests are often repeated, since everyday factors can distort the results [3].
No medicine replaces the missing receptor. Treatment prevents bleeding where it can be predicted, stops it when it starts, and protects iron levels. Many people need nothing day to day [6].
Antifibrinolytic medicines. Tranexamic acid and aminocaproic acid help hold a clot in place rather than form one. They come as tablets, as a mouthwash for gum bleeding and on soaked gauze for nosebleeds, and are the usual first step for mild bleeding, heavy periods and dental work [4,5,6].
Recombinant factor VIIa. This laboratory-made clotting protein boosts clot formation in a way that works around the missing receptor. It is licensed here in the United States for people whose platelet transfusions no longer work, and in Europe also where platelets are not readily available. It carries a warning about blood clots [8,9].
Platelet transfusions, and an important catch. Donated platelets carry a working receptor, so they can stop severe bleeding. The immune system may then treat that receptor as foreign, since the person’s own platelets never had it, and make antibodies against it, after which later transfusions can stop working. In an international study of 218 people, 30 percent had anti-platelet antibodies and 16 percent had a transfusion that failed to work [7]. Transfusions are therefore kept for serious bleeding and major surgery, matched and filtered where possible, and avoided in girls and women of childbearing age where possible, since these antibodies can cross the placenta and affect a baby’s platelets [4,7]. Antibody testing is recommended at diagnosis and after any transfusion, though it is not done everywhere [7,11].
Procedures, periods and childbirth. Dental work and surgery are planned in advance with the treatment center, usually with an antifibrinolytic and recombinant factor VIIa, which controlled around 90 percent of reported bleeds, and platelets in reserve [4,10,11]. Heavy periods are treated with an antifibrinolytic first, then hormonal options such as the combined pill or a hormone-releasing coil [4,5]. Pregnancy needs a specialist team, since bleeding at delivery is a real risk and epidural anesthesia is generally avoided [3,4].
The one curative option. A transplant of blood-forming stem cells from a donor replaces the bone marrow with one that makes normal platelets, and reported cases have been cured, including some with antibodies [4,15,16]. It is reserved for severe cases, usually children whose bleeding cannot be controlled, since the transplant itself risks serious complications and death [15].
Care works best through a bleeding disorder treatment center reachable at any hour, with hematology, dentistry, gynecology and laboratory expertise [3,4].
Carry written details of the diagnosis, the treatment plan and the center’s emergency number, and consider a medical alert bracelet [3,4]. Keep dental care up to date, since healthy gums bleed less [4]. Aspirin and anti-inflammatory painkillers such as ibuprofen are avoided, since they switch off part of the platelet response that still works, and injections go under the skin rather than into muscle where possible. Tell any new doctor, dentist, pharmacist or midwife before a procedure or a new medicine [6]. Contact sports are usually discouraged, swimming and walking encouraged, and iron levels checked, since slow blood loss adds up [4,5,6].
The emotional side is real. A study of people with the condition found frequent low mood and social isolation, and most had missed school or work because of bruising or bleeding [19]. Support from a specialist team, and from others living with it, helps [22].
Clinical trials are research studies that test whether a treatment works and is safe. This is an active research area, so studies do come up, though fewer than for common conditions. Deciding is personal, and it helps to take it in steps.
Be clear on what a study actually involves:
Every trial has rules about who can take part. These are called eligibility criteria. Some describe who can join, others who cannot. For a study here they might include a diagnosis confirmed by platelet aggregation testing, flow cytometry or genetic testing, a particular type such as type I, an age range, a set number of bleeding episodes in the past year, a recent record of antibodies against platelets, and no recent platelet transfusion or stem cell transplant.
trialport’s medifit helps people consider information related to possible medical suitability. It does not diagnose a condition, confirm eligibility or replace formal screening by the study team.
Explore Glanzmann thrombasthenia clinical trials through trialport
Medical suitability is only part of it. A study can look right on paper and still be hard in practice. Worth thinking through:
trialport’s readifit helps people reflect on their understanding, motivation, time, routines, support, emotions and practical arrangements.
Useful questions to put to a research team:
Taking part is voluntary. A person can ask questions, speak with people they trust and choose not to participate.
Search for clinical trials at app.trialport.com.
Three areas are moving:
Study status checked: 3 August 2026. Research moves and what is being studied changes, so this list will date. For current information, search at app.trialport.com.
One charity is devoted to this condition: Glanzmann’s Research Foundation in the United States, which funds research and publishes first-person accounts [22]. Internationally, the World Federation of Hemophilia lists treatment centers and member organizations country by country, and its booklet on inherited platelet function disorders is free to read [5,23]. In the United States the National Bleeding Disorders Foundation covers platelet disorders and treatment centers [17]. In the United Kingdom The Haemophilia Society publishes a factsheet on this condition [6,24], and Rare Disease UK covers rare conditions [25]. In Australia Haemophilia Foundation Australia has a dedicated page and personal stories [21], and in Canada Bleeding Disorders Canada has regional chapters [27]. Provision elsewhere is uneven, and specialist testing and treatment are hardest to reach in lower-income countries [3].
My platelet count is normal, so how can I have a platelet problem?
The count and the job are different things. This condition affects what platelets do, not how many there are, so the count and the standard clotting tests come back normal. Only specialist platelet function tests find it [3,5,6].
Is it the same as hemophilia?
No. In hemophilia a clotting protein is missing and joint bleeding is typical. Here the platelets cannot clump, and bleeding is mostly from skin, nose, gums, gut and womb [3,12].
Can it be cured?
A stem cell transplant from a donor is the only treatment that removes it, and it is kept for severe cases since it carries real risks [4,15,16].
Why might a platelet transfusion stop working?
The immune system can make antibodies against the receptor a person’s own platelets never had. Donated platelets are then cleared quickly and may stop working, so transfusions are saved for serious situations [4,7].
Will my children have it?
Only if they inherit a changed copy from both parents. If both parents are carriers, each pregnancy carries a 1 in 4 chance [2].
What about pregnancy and childbirth?
Pregnancy itself usually goes well. Delivery and the days afterward carry a real bleeding risk and need a plan agreed in advance, including antibody testing, since antibodies can affect a baby’s platelets [3,4,7].
Which painkillers are safe?
Aspirin and anti-inflammatory painkillers such as ibuprofen are avoided, since they interfere with platelets. Ask your treatment center what to use instead [6].
Written by: trialport editorial team
Reviewed by: Keith Berelowitz, Founder and CEO, trialport
Reviewed on: 3 August 2026
Next review due: 3 August 2027
References last checked: 3 August 2026